

DAFTAR PUSTAKA

- Amalia, M., Hidayati, P. H., Yanti, A. K. E., Vitayani, S., & Gayatri, S. W. (2023). Karakteristik pasien sirosis hepatitis. *UMI Medical Journal*, 8(1), 53-61.
- American Diabetes Association. (2025). Standards of care in diabetes 2025. *Diabetes Care*. *Diabetes Care*, 48 (1), 20–42.
- Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., & Wong, F. (2021). Diagnosis, evaluation, and management of ascites and hepatorenal syndrome in cirrhosis: AASLD practice guidance. *Hepatology*, 74(2), 1014–1048.
- Boivin, Z., Pérez, V., & Lee, M. (2023). Impact of cirrhosis on pneumonia-related outcomes: A review. *Journal of Clinical Medicine*, 12(4), 11-20.
- Boursier, J., Anty, R., Carette, C., Cariou, B., Castera, L., Caussy, C., Fontaine, H., Garioud, A., Gourdy, P., Guerci, B., Guillaume, M., Michot, N., Minello, A., Ouizeman, D. J., Serfaty, L., Bonnet, F., Verges, B., & Petit, J.-M. (on behalf of AFEF and SFD). (2021). Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. *Diabetes & Metabolism*, 47(5), 232-235
- Brunton, L. L., & Knollmann, B. C. (2023). *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. New York: McGraw Hill.
- Christian Yong, B. J., & Vidor, M. (2022). Sirosis Hepatis - Reversibel atau Irreversibel. *CDK-300*, 49(1), 44-47.
- Darmawan, H., & Agustina, A. (2023). Sirosis Hepatis. *Jurnal Ventilator*, 1(4), 245-261.
- Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023). Global burden of liver disease 2023 update. *Journal of Hepatology*, 79(2), 516–537.
- Dever, J. B., & Sheikh, M. Y. (2020). Review article: Bacterial infections in cirrhosis Pathogenesis and management. *World Journal of Gastroenterology*, 26(26), 3387–3400.
- Dewi, K. P., Abida, A. N., Aswandani, A., Anggraeni, B. A. U., Shofa, D. A., Aunurrahman, M. R. A., & Husna, N. F. (2024). Hepatic Cirrhosis: A Literature Review. *Jurnal Biologi Tropis*, 24(1), 35-41.
- DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2020). *Pharmacotherapy: A pathophysiologic approach* (11st ed). New York: McGraw-Hill Education.
- Efmisa, A. K., Armenia, & Almasdy, D. (2023). Use of Potentially Hepatotoxic Drugs in Liver Cirrhosis Patients: A Review. *Journal of Pharmaceutical*

and Sciences, 6(2), 766-771.

- El Gazzar, N. A. E. N., Ali, L. A., Yousef, M., & Elfert, A. (2022). Prevalence of arterial hypertension in liver cirrhosis and correlation with the severity of liver disease. *International Journal of Health Sciences*, 6(5), 1230–1234
- European Association for the Study of the Liver. (2018). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *Journal of Hepatology*, 69(2), 406–460.
- European Association for the Study of the Liver. (2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. *Journal of Hepatology*, 75(3), 659–689.
- Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., McIntyre, L., Ostermann, M., Prescott, H. C., Schorr, C., Simpson, S., Wiersinga, W. J., Alshamsi, F., Angus, D. C., Arabi, Y., Azevedo, L., Beale, R., Beilman, G., Levy, M. M. (2021). Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. *Intensive Care Medicine*, 47(11), 1181–1247.
- Fadlallah, H., El Masri, D., Bahmad, H. F., Abou-Kheir, W., & El Masri, J. (2025). Update on the complications and management of liver cirrhosis. *Medical Sciences*, 13(1), 13
- Farida, A., & Anindya, C. (2021). Analysis of Potential Drug Interactions in Liver Cirrhosis Patients. *Jurnal Farmasi Galenika*, 7(1), 17–28.
- Feldman, M., Friedman, L. S., Brandt, L. J., Chung, R. T., Rubin, D. T., & Wilcox, C. M. (2021). *Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, and Management* (11st ed). Philadelphia: Elsevier.
- Garcia-Tsao, G., Abraldes, J. G., Rich, N. E., & Wong, V. W.-S. (2024). AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review. *Gastroenterology*, 166(1), 202–210.
- Gines, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021). Liver cirrhosis. *The Lancet*, 398(10308), 1359–1376
- Hasan, I., Nababan, S. H. H., Handayu, A. D., Aprilicia, G., & Gani, R. A. (2023). Scoring system for predicting 90-day mortality of in-hospital liver cirrhosis patients at Cipto Mangunkusumo Hospital. *Gastroenterology*, 23(1), 190-194.
- Hayward, K. L., & Weersink, R. A. (2020). Improving medication-related outcomes in chronic liver disease. *Hepatology Communications*, 4(11), 1562–1577.
- Kementerian Kesehatan Republik Indonesia. (2023). *Mediacom edisi 156*. Diakses dari <https://kemkes.go.id/id/rilis-kesehatan/mediakom-156>.

- Khan, S., & Linganna, M. (2023). Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. *Cleveland Clinic Journal of Medicine*, 90(4), 233–244.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International*, 105(4S), S117–S314.
- Levitt, D. G., & Levitt, M. D. (2018). A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans. *Clinical and Experimental Gastroenterology*, 11(3), 193–215.
- Liu, Y. B., Chen, S., & Wu, J. X. (2022). Epidemiology of cirrhosis and complications. *World Journal of Gastroenterology*, 28(41), 5910–5929.
- Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *American Journal of Respiratory and Critical Care Medicine*, 200(7), e45–e67.
- Mohammed, Y., Abdosh, T., Mishore, K. M., Ahmed, M., Adem, H. A., Usso, A. A., Abraham, R. Y., Siyo, A. A., & Edin, A. (2025). Spontaneous bacterial peritonitis and associated factors among patients with cirrhotic ascites attending public hospitals in Harari region, eastern Ethiopia. *SAGE Open Medicine*, 13(20), 1–8.
- Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: update 2020. *J Hepatol*. 73(1), 117–137.
- Muti, A. F., & Octavia, N. (2018). Kajian Penggunaan Obat Berdasarkan Indikator Peresepan WHO dan Prescribing Errors Di Apotek Naura Medika, Depok. *Sainstech Farma*, 11(1), 25-29.
- Nadim, M. K., Kellum, J. A., Forni, L., Francoz, C., Asrani, S. K., Ostermann, M., Allegretti, A. S., Neyra, J. A. (2024). Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. *Journal of Hepatology*, 80(3), 514–535.
- Ndraha, S., Imelda, I., Tendean, M., & Santoso, M. (2019). Komplikasi penderita sirosis hati di RSUD Koja pada bulan Juli–November 2017. *Jurnal Kedokteran Meditek*, 24(67), 17–20.
- Nurdin, I., & Hartati, S. (2019). *Metodologi Penelitian Sosial*. Surabaya: Media Sahabat Cendekia.

- Nusrat, S., Khan, M. S., Fazili, J., & Madhoun, M. F. (2014). Cirrhosis and its complications: Evidence based treatment. *World Journal of Gastroenterology*, 20(18), 5442–5460.
- Sanyal, A. J., Singh, V., Sharma, B. C., & Mullen, K. D. (2024). Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. *Hepatology Communications*, 8(6), 100–110.
- Schwinghammer, T. L., DiPiro, J. T., Ellingrod, V. L., & DiPiro, C. V. (2021). *Pharmacotherapy handbook* (11st ed.). New York: McGraw-Hill Education.
- Sharma, B., & John, S. (2021). *Hepatic Cirrhosis*. Treasure Island: Statpearls Publishing Llc.
- Singh, J., Ebaid, M., & Saab, S. (2024). Advances in the management of complications from cirrhosis. *Gastroenterology Report*. 12(3), 123-126
- Suk, K. T., Kim, D. J., Kim, Y. S., et al. (2021). Clinical aspects of portal hypertension. *Clinical and Molecular Hepatology*, 27(3), 364–381.
- Sulistyoningrum, E., & Murtisiwi, L. (2020). Gambaran Pereseapan Pasien Sirosis Hati di Instalasi Rawat Jalan Rumah Sakit Panti Waluyo Surakarta. *Journal of Pharmacy*, 9(1), 1-7.
- Tapper, E. B., & Parikh, N. D. (2023). Cirrhosis. *JAMA*, 329(18), 1589–1602.
- Thaha, R., Yunita, E., & Sabir, M. (2020). Sirosis hepatitis. *Jurnal Medical Profession (MedPro)*, 2(3), 166-170.
- Theodorakopoulou, M., Ortiz, A., Fernandez-Fernandez, B., Kanbay, M., Minutolo, R., & Sarafidis, P. A. (2024). Guidelines for the management of hypertension in CKD patients: where do we stand in 2024? *Clinical Kidney Journal*, 17(Suppl 2), ii36–ii50.
- Tsoris, A., & Marlar, C. A. (2023). *Use of the Child-Pugh score in liver disease*. Treasure Island: StatPearls Publishing.
- Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2021). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by AASLD and EASL. *Hepatology*, 71(2), 712–735.
- Virma, S. G., Adelin, P., & Mona, L. (2023). Karakteristik pasien sirosis hepatitis di Rumah Sakit Dr. Achmad Mochtar Bukittinggi periode tahun 2018– 2020. *Jurnal Kedokteran Nanggroe Medika*, 6(1), 1-10.
- Von Maldeghem, E., Zimmermann, K., Mester, P., Pavel, V., Athanasoulas, G., Kirsch, L., Kolben, D., Rusch, S., Schlosser-Hupf, S., Müller, M., & Schmid, S. (2025). Sepsis drives severity and mortality in acute-on-chronic liver failure among ICU patients with alcohol-related cirrhosis: A retrospective single center study. *Journal of Clinical Medicine*, 14(19), 25-

- Wan, S.-Z., Nie, Y., Zhang, Y., Liu, C., & Zhu, X. (2020). Assessing the prognostic performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin scores in patients with decompensated cirrhosis: A large Asian cohort from gastroenterology department. *Disease Markers*, 8(14), 111-117
- Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Jr., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Jr., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Sr., Williamson, J. D., & Wright, J. T., Jr. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 71(19), e127–e248.
- World Health Organization. (2020). *Global report on access to hepatitis C treatment*. <https://www.who.int/publications/i/item/9789240019003>
- Zelege, T. K., Bazezew, Z. A., & Abebe, R. B. (2023). The burden of inappropriate prescriptions and predictors for hospitalized patients with liver cirrhosis in Ethiopia. *Hepatic Medicine: Evidence and Research*, 15(4), 129–141.

